What is the Vaishali Pharma PE ratio today?
Vaishali Pharma's PE ratio is 9.5 at the 30 October 2026 close (₹6.42 a share): a market capitalisation of ₹41.9 crore divided by consolidated net profit of ₹4.4 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹4.2 crore) it is 10.1.
What is the Vaishali Pharma net worth?
Vaishali Pharma's net worth — shareholders' equity in its consolidated balance sheet — was ₹69.1 crore on 31 March 2026. Its market value is a different figure: a market capitalisation of ₹41.9 crore at the 30 October 2026 close.
What is the Vaishali Pharma book value per share?
Vaishali Pharma's book value per share was ₹10.60 on 31 March 2026: shareholders' equity of ₹69.1 crore divided by the 6.52 crore shares in issue. The share price at the 30 October 2026 close was ₹6.42.
What is the Vaishali Pharma PB ratio (price to book value)?
Vaishali Pharma's price-to-book (PB) ratio is 0.61 at the 30 October 2026 close: a market capitalisation of ₹41.9 crore divided by shareholders' equity (book value) of ₹69.1 crore on 31 March 2026. That is a book value of ₹10.60 per share against a share price of ₹6.42.
Is Vaishali Pharma debt free?
No. Vaishali Pharma had borrowings of ₹18.5 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.27. Its cash and current investments were ₹1.4 crore, so its net debt was ₹17.1 crore.
What is the Vaishali Pharma ROE and ROCE?
In FY26, Vaishali Pharma's return on equity (ROE) was 6.2% and its return on capital employed (ROCE) was 4.9%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities).
What is the Vaishali Pharma market cap?
Vaishali Pharma's market capitalisation was ₹41.9 crore at the 30 October 2026 close: 6.52 crore shares at ₹6.42 each.
What is the Vaishali Pharma debt to equity ratio?
Vaishali Pharma's debt-to-equity ratio was 0.27 on 31 March 2026: borrowings of ₹18.5 crore against total equity of ₹69.1 crore.
What is the Vaishali Pharma EPS?
Vaishali Pharma's basic earnings per share (EPS) were ₹0.32 in FY26.
What is the Vaishali Pharma promoter holding?
Promoters held 31.61% of Vaishali Pharma on 30 September 2026, unchanged from the previous quarter and up 5.29 percentage points from 26.32% a year earlier, according to the shareholding pattern filed with NSE.
What is the Vaishali Pharma shareholding pattern?
On 30 September 2026, Vaishali Pharma's shares were held by promoters 31.61% and retail and other non-institutional investors 68.39%.
What is the Vaishali Pharma free cash flow?
In FY26, Vaishali Pharma generated ₹44 lakh of cash from operations and spent ₹46 lakh on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹2.3 lakh. In FY25 it was −₹18 crore.
What are the Vaishali Pharma latest quarterly results?
Vaishali Pharma's latest results are for Q1 FY27 (April–June 2026), filed on 14 August 2026: consolidated net profit ₹1.5 crore; revenue from operations ₹22.9 crore.
What is the Vaishali Pharma revenue and profit in FY26?
In FY26 (April 2025–March 2026), Vaishali Pharma's consolidated net profit was ₹4.2 crore, on revenue from operations of ₹109 crore.
When are the Vaishali Pharma next results?
Vaishali Pharma has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.
How does Vaishali Pharma compare with its peers?
On FY26 consolidated figures, against Tembo Global Industries, Total Transport Systems and ShreeOswal Seeds And Chemicals: Vaishali Pharma's operating margin of 3.2% is the third highest of the four (Tembo Global Industries 12.5%, Total Transport Systems 1.8%, ShreeOswal Seeds And Chemicals 5.6%; peer average 6.6%); its return on equity of 6.2% is the lowest of the four (Tembo Global Industries 27.5%, Total Transport Systems 9.0%, ShreeOswal Seeds And Chemicals 15.2%; peer average 17.2%).
How does the Vaishali Pharma PE ratio compare with its peers?
At the 30 October 2026 closing prices, on FY26 net profit, Vaishali Pharma's PE ratio is 10.1, the lowest of the four: Tembo Global Industries 10.6, Total Transport Systems 14.2 and ShreeOswal Seeds And Chemicals 13.8, a peer average of 12.9. Each is the company's market capitalisation at that price divided by its FY26 net profit.
Vaishali Pharma vs Tembo Global Industries: how do they compare?
In FY26, Vaishali Pharma earned net profit of ₹4.2 crore on revenue of ₹109 crore, against ₹91.3 crore on ₹1,090 crore for Tembo Global Industries. Vaishali Pharma's operating margin was 3.2% (Tembo Global Industries 12.5%) and its return on equity 6.2% (Tembo Global Industries 27.5%). At the 30 October 2026 close, Vaishali Pharma's market capitalisation was ₹41.9 crore against ₹968 crore for Tembo Global Industries, and its PE ratio on FY26 profit 10.1 against 10.6.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
